LUND, Sweden – Cellevate, an innovative biotech company developing next-generation cell culture systems to revolutionize biomanufacturing, announced today the successful closure of its recent second seed round led by Industrifonden in syndication with the European Innovation Council Fund (EIC Fund), securing a total of 3.2 MEUR. By achieving commercial and technical readiness in Q3 2024, Cellevate is preparing for the aggressive commercialization of the first product, Cellevat3d™ nanofiber microcarriers in November 2024.